Abridge, the leader in generative AI for clinical documentation, announced an additional $150 million investment, leveraging momentum from their product's rapid uptake among health systems throughout the nation. This raise comes just 4 months after their $30M Series B, and is one of the largest funding rounds made to date in generative AI for healthcare.

The Series C investment was led by Lightspeed Venture Partners, who will also join the board. Other new and existing investors continuing to support the company include co-lead Redpoint Ventures, with support from IVP, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Mass General Brigham Artificial Intelligence and Digital Innovation Fund (AIDIF), Kaiser Permanente Ventures, and CVS Health Ventures.